NCT06397677 Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
| NCT ID | NCT06397677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Rheumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2024-01-22 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2024-01-22 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Eligibility Criteria
Inclusion Criteria: * Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria * 18 years of age or older Exclusion Criteria: * Prior medication treatment specifically for RA-ILD * Inability to give informed consent * Pregnant women
Contact & Investigator
Joyce S Lee
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT06397677 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06397677 currently recruiting?
Yes, NCT06397677 is actively recruiting participants. Contact the research team at haylie.lengel@cuanschutz.edu for enrollment information.
Where is the NCT06397677 trial being conducted?
This trial is being conducted at San Francisco, United States, Aurora, United States, Kansas City, United States, Ann Arbor, United States.
Who is sponsoring the NCT06397677 clinical trial?
NCT06397677 is sponsored by University of Colorado, Denver. The principal investigator is Joyce S Lee at University of Colorado, Denver. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.